Pulsara Around the World - 2025 Recap and January 2026
December Recap After an incredibly busy events year with 102 conferences, trade shows, and sponsorships, December was on the slower side for us, with...
1 min read
Brittney Nelson, BSN, RN, SCRN
:
Apr 11, 2017

“I think it will help you as a doctor to know you’re doing a treatment not only for 3 months, but that the treatment benefit is going to last for at least 2 years,” said Yvo Roos, MD. “It’s going to help you be more convincing to the relatives that you’re doing the right thing, that you’re doing something that’s really going to help them."
The above quote is in reference to new long-term followup data published as of April 6th, 2017, which now confirms and extends the outcomes of the MR CLEAN endovascular therapy trial in acute ischemic stroke patients. The results show that 1 out of every 3 patients treated with catheter based intervention are returning home to care for themselves within 3 months and these results are durable up to 2 years! Read the full details of the follow up data right here.
December Recap After an incredibly busy events year with 102 conferences, trade shows, and sponsorships, December was on the slower side for us, with...
Editor's Note: In July 2025, EMS1 and Fitch & Associates released their annual EMS trend survey, What Paramedics Want, proudly sponsored by Pulsara....
Published research shows how using Pulsara, alongside standardized field activation and a focus on stakeholder relationships, improves STEMI care and...